Morning Briefing
Summaries of health policy coverage from major news organizations
FDA Approves New Hepatitis C Drug, Harvoni
Insurers and patients are decrying the cost for the new drug, nearly $95,000 for a 12-week course of treatment, which is more expensive than Gilead's other hepatitis C drug, Sovaldi. But unlike some hepatitis C treatments, Harvoni can be taken without injections usually given to hepatitis C patients.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
